Amylyx Pharmaceuticals said its Phase 3 LUCIDITY trial of avexitide met its primary endpoint in patients with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. According to the company's press release, avexitide reduced composite Level 2 and Level 3 hypoglycemic events by 55% compared with placebo.

The trial enrolled 78 adults. Participants in the avexitide arm averaged 0.55 events per week, compared with 1.24 events per week in the placebo arm. The company reported that all prespecified secondary endpoints were also met. These included reductions of 63% in self-monitored Level 2 events, 47% in Level 3 events adjudicated by an Event Adjudication Committee, and 42% in continuous glucose monitor-detected Level 2 events.

Participants were randomized 3:2 to receive 90 mg of avexitide subcutaneously once daily or placebo over a 16-week double-blind treatment period. The company said more than 90% completed the treatment period. The report states that adverse events were mainly gastrointestinal and injection-site related and were generally mild to moderate. It also says the trial reported no deaths and no treatment-related serious adverse events.

Amylyx said it plans to submit a New Drug Application by year end and is preparing for a potential commercial launch in 2027, if approved. The FDA previously granted avexitide Breakthrough Therapy Designation for this condition. The report estimates that about 160,000 people in the U.S. are affected, and it notes that no FDA-approved therapies currently exist for the condition.